Skip to main content

Advertisement

SpringerLink
Log in

Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Cytoreductive nephrectomy (CN) has an established role against metastatic renal cell carcinoma (mRCC) in properly selected patients and offers a survival advantage when performed prior to cytokine therapy. With the emergence of new, effective targeted molecular therapies for mRCC, well-designed prospective trials are needed to clarify the biologic effects of CN to determine when and for whom CN should be performed in the context of targeted systemic therapy. Consequently, a thorough characterization of the systemic effects afforded by CN is imperative for developing individualized treatment strategies that effectively address the underlying biology of mRCC while maximizing patient quality of life during therapy. Until then, debulking surgery, which provides a survival benefit for select patients with mRCC, should continue to be used in patients before or after targeted systemic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43–66.

    Article  PubMed  Google Scholar 

  2. Motzer RJ, Bacik J, Schwartz LH, et al.: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004, 22:454–463.

    Article  PubMed  Google Scholar 

  3. Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005, 23:1028–1043.

    Article  PubMed  CAS  Google Scholar 

  4. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125–134.

    Article  PubMed  CAS  Google Scholar 

  5. Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115–124.

    Article  PubMed  CAS  Google Scholar 

  6. Hudes G, Carducci M, Tomczak P, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271–2281.

    Article  PubMed  CAS  Google Scholar 

  7. Montie JE, Stewart BH, Straffon RA, et al.: The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977, 117:272–275.

    PubMed  CAS  Google Scholar 

  8. Dekernion JB, Ramming KP, Smith RB: The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978, 120:148–152.

    PubMed  CAS  Google Scholar 

  9. Flanigan RC, Salmon SE, Blumenstein BA, et al.: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655–1659.

    Article  PubMed  CAS  Google Scholar 

  10. Mickisch GH, Garin A, van Poppel H, et al.: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966–970.

    Article  PubMed  CAS  Google Scholar 

  11. Flanigan RC, Mickisch G, Sylvester R, et al.: Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004, 171:1071–1076.

    Article  PubMed  Google Scholar 

  12. Marcus SG, Choyke PL, Reiter R, et al.: Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993, 150:463–466.

    PubMed  CAS  Google Scholar 

  13. Vieweg J, Su Z, Dahm P, Kusmartsev S: Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007, 13:727s–732s.

    Article  PubMed  CAS  Google Scholar 

  14. Kudoh S, Redovan C, Rayman P, et al.: Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. J Immunother (1997) 1997, 20:479–487.

    Article  CAS  Google Scholar 

  15. Schleypen JS, Baur N, Kammerer R, et al.: Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006, 12:718–725.

    Article  PubMed  CAS  Google Scholar 

  16. Tatsumi T, Kierstead LS, Ranieri E, et al.: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002, 196:619–628.

    Article  PubMed  CAS  Google Scholar 

  17. Tatsumi T, Herrem CJ, Olson WC, et al.: Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003, 63:4481–4489.

    PubMed  CAS  Google Scholar 

  18. Uzzo RG, Rayman P, Kolenko V, et al.: Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappa B activation in T cells. J Clin Invest 1999, 104:769–776.

    Article  PubMed  CAS  Google Scholar 

  19. Gatenby RA, Gawlinski ET, Tangen CM, et al.: The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res 2002, 62:5218–5222.

    PubMed  CAS  Google Scholar 

  20. Dosquet C, Coudert MC, Lepage E, et al.: Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997, 3:2451–2458.

    PubMed  CAS  Google Scholar 

  21. Edgren M, Lennernäs B, Larsson A, Nilsson S: Serum concentrations of VEGF and β-FGF in renal cell, prostate and urinary bladder carcinomas. Anticancer Res 1999, 19:869–873.

    PubMed  CAS  Google Scholar 

  22. Jacobsen J, Grankvist K, Rasmuson T, et al.: Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004, 93:297–302.

    Article  PubMed  CAS  Google Scholar 

  23. Feldman AL, Alexander HR Jr, Yang JC, et al.: Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 2002, 95:1637–1643.

    Article  PubMed  CAS  Google Scholar 

  24. Clayman RV: Laparoscopic radical nephrectomy: oncologic efficacy. J Urol 2005, 173:1201.

    Article  PubMed  Google Scholar 

  25. Permpongkosol S, Chan DY, Link RE, et al.: Laparoscopic radical nephrectomy: long-term outcomes. J Endourol 2005, 19:628–633.

    Article  PubMed  Google Scholar 

  26. Walther MM, Lyne JC, Libutti SK, Linehan WM: Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology 1999, 53:496–501.

    Article  PubMed  CAS  Google Scholar 

  27. Rabets JC, Kaouk J, Fergany A, et al.: Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 2004, 64:930–934.

    Article  PubMed  Google Scholar 

  28. Matin SF, Madsen LT, Wood CG: Laparoscopic cytoreductive nephrectomy: the M.D. Anderson Cancer Center experience. Urology 2006, 68:528–532.

    Article  PubMed  Google Scholar 

  29. Jonasch E: Presurgical therapy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2007, 7:73–78.

    Article  PubMed  CAS  Google Scholar 

  30. Wood CG: Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 2007, 13:697s–702s.

    Article  PubMed  Google Scholar 

  31. Motzer RJ, Bacik J, Mariani T, et al.: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002, 20:2376–2381.

    Article  PubMed  Google Scholar 

  32. Kassouf W, Sanchez-Ortiz R, Tamboli P, et al.: Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol 2007, 178:1896–1900.

    Article  PubMed  Google Scholar 

  33. Fallick ML, McDermott DF, LaRock D, et al.: Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997, 158:1691–1695.

    Article  PubMed  CAS  Google Scholar 

  34. Han KR, Pantuck AJ, Bui MH, et al.: Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 2003, 61:314–319.

    Article  PubMed  Google Scholar 

  35. Wood CG: The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. Urol Clin North Am 2003, 30:581–588.

    Article  PubMed  Google Scholar 

  36. Pantuck AJ, Zisman A, Dorey F, et al.: Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003, 97:2995–3002.

    Article  PubMed  Google Scholar 

  37. Vasselli JR, Yang JC, Linehan WM, et al.: Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001, 166:68–72.

    Article  PubMed  CAS  Google Scholar 

  38. Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530–2540.

    PubMed  CAS  Google Scholar 

  39. Leibovich BC, Cheville JC, Lohse CM, et al.: A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005, 174:1759–1763; discussion 1763.

    Article  PubMed  Google Scholar 

  40. Motzer RJ, Figlin RA, Hutson TE, et al.: Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):5024.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Unit 1373, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Surena F. Matin

Authors
  1. Vitaly Margulis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher G. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eric Jonasch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Surena F. Matin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Surena F. Matin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Margulis, V., Wood, C.G., Jonasch, E. et al. Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Curr Oncol Rep 10, 253–258 (2008). https://doi.org/10.1007/s11912-008-0038-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-008-0038-3

Keywords

Search

Navigation